The FDA has approved two new indications for trastuzumab deruxtecan (T-DXd; Enhertu, AstraZeneca/Daiichi Sankyo), broadening the drug’s use for patients with HER2-positive early breast cancer and moving the therapy into potentially curative treatment settings. The expanded indications for the anti-HER2 antibody-drug conjugate cover both the neoadjuvant and adjuvant settings. …
Read More
FDA Expands Use of T-DXd in Early HER2+ Breast Cancer
